UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 30, 2007

COLGATE-PALMOLIVE COMPANY

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation) 1-644-2 (Commission File Number) 13-1815595 (IRS Employer Identification No.)

300 Park Avenue, New York, NY (Address of Principal Executive Offices) 10022 (Zip Code)

Registrant's telephone number, including area code (212) 310-2000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Dere-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On October 30, 2007, Colgate-Palmolive Company issued a press release announcing its earnings for the quarter ended September 30, 2007. This press release is attached as Exhibit 99 and is incorporated herein by reference.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) *Exhibits*. The following exhibit is filed with this document:

Exhibit	
Number	Description
99	Press release, dated October 30, 2007, issued by Colgate-Palmolive Company

EXHIBIT INDEX

Exhibit <u>Number</u> 99 Description

Press release, dated October 30, 2007, issued by Colgate-Palmolive Company

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

COLGATE-PALMOLIVE COMPANY

By: /s/ STEPHEN C. PATRICK

Name: Stephen C. Patrick Title: Chief Financial Officer

Date: October 30, 2007

Colgate Announces Strong 3rd Quarter, Exceeding Expectations Operating and Net Profit Up Double-Digit Excellent Sales and Volume Growth Worldwide

New York, New York, October 30, 2007... Colgate-Palmolive Company (NYSE:CL) today announced excellent worldwide sales and unit volume growth together with double-digit earnings growth for third quarter 2007. Worldwide sales grew 12.0% to \$3,528.2 million and unit volume grew 5.5%, as reported. Excluding divestments, worldwide sales and unit volume grew 13.0% and 6.5%, respectively. Global pricing increased 1.0%, and foreign exchange added 5.5%. The very strong top-line growth was supported by a 12% increase in worldwide advertising spending.

Third quarter 2007 results include \$36.3 million of aftertax charges related to the 2004 Restructuring Program and a \$10.0 million non-cash, aftertax SFAS 88 pension charge with no such comparable pension charge in 2006. This SFAS 88 pension charge is a result of lump sum payments of normal retirement benefits associated with a nonqualified retirement plan in the United States. In the year ago quarter, restructuring charges were \$58.5 million aftertax.

As reported, gross profit margin increased 120 basis points to 56.2%. Excluding restructuring charges, gross profit margin increased 80 basis points to a record 57.3% on top of the 140 basis point improvement in the year ago period, despite significant increases in agricultural commodity costs in the Hill's division.

Operating profit as reported increased 22% versus third quarter 2006 to \$668.8 million, 19.0% of sales. Excluding restructuring and SFAS 88 charges, operating profit rose 16%

to \$735.3 million. On the same basis, operating profit margin was 20.8% of sales, up 70 basis points versus the year ago period.

Reported net income and diluted earnings per share in third quarter 2007 were \$420.1 million and \$.77, respectively. Excluding restructuring and SFAS 88 charges, net income in the quarter increased 16% versus third quarter 2006 to a record \$466.4 million, and diluted earnings per share increased 18% to \$.86, also a record. In third quarter 2006, reported net income and diluted earnings per share were \$344.1 million and \$.63, respectively, and net income and diluted earnings per share excluding restructuring charges were \$402.6 million and \$.73, respectively.

Net cash provided by operations year to date increased by 20% to \$1,638.7 million after building inventories to support the business during factory closings related to the 2004 Restructuring Program. Colgate's strong balance sheet strengthened even further during the period with key measures improving and net debt declining versus third quarter 2006 and second quarter 2007. End of third quarter 2007 working capital improved to 2.4% of sales versus 2.6% in the comparable 2006 period.

Ian Cook, President and CEO commented, "We are delighted that our excellent top and bottom line growth momentum continued this quarter with every geographic region delivering sales and profit increases. This is the fourth consecutive quarter of double-digit sales and profit growth worldwide, and our 18% increase in earnings per share, excluding restructuring and SFAS 88 charges, is the highest quarterly increase we have seen in over four years.

"Colgate's market shares are strong and getting stronger in key markets around the world. Colgate strengthened its global leadership in toothpaste and manual toothbrushes during the quarter and our global market share in both categories increased to all-time record highs.

"The gross margin expansion and other savings programs helped fund higher advertising spending across all operating divisions while still generating doubledigit operating profit growth worldwide.

"We are of course pleased that the excellent operating profitability delivered higher than expected net income and earnings per share even after the significant increase in advertising spending and absorbing a higher than expected tax rate in the quarter."

Mr. Cook further commented, "As we look to the balance of the year we are confident that the strong top-line growth will continue, driven by our very full new product pipeline with an array of impactful, integrated marketing campaigns to support them. We expect gross profit margin, excluding restructuring charges, to be up within our targeted range of 75 to 125 basis points for this year and next year as well, as a result of our ongoing cost-savings initiatives, the benefits from restructuring, efficiencies in promotional programs and a continued shift towards higher-margin products.

"All this adds to our strong confidence that we will deliver double-digit earnings per share growth for the balance of 2007 and full year 2008."

At 11:00 a.m. ET today, Colgate will host a conference call to elaborate on third quarter results. To access this call as a webcast, please go to Colgate's web site at http://www.colgate.com.

The following are comments about divisional performance. See attached Geographic Sales Analysis and Segment Information schedules for additional information on divisional sales and operating profit.

North America (20% of Company Sales)

Positive growth continued in North America, fueled by new product sales and market share gains. As reported, sales and unit volume grew 3.0% and 1.5%, respectively. Excluding the divestiture of the Canadian household bleach business, sales and unit volume grew 4.5% and 3.0%, respectively. Pricing increased 0.5% and foreign exchange

added 1.0%. North American operating profit increased 19% during the quarter to an all-time record level.

In the U.S., new product launches in the super-premium category are contributing to growth in oral care. Colgate Total Advanced Clean toothpaste, supported by an integrated marketing campaign featuring Brooke Shields and an expansive professional sampling program, helped drive market share for Colgate Total toothpaste to its highest quarterly share ever at 15.3%. Colgate Max Fresh BURST toothpaste, infused with 50% more mini breath strips, continues to build incremental market share for the Max Fresh equity, now at 3.9% year to date. Colgate's share of the manual toothbrush market is 25.6% year to date, up 2.0 share points versus year ago, fueled by the continued success of Colgate 360° manual toothbrush and its latest variant Colgate 360° Sensitive.

Positive growth momentum for both sales and profits in North America is expected to continue. Successful new products contributing to growth in other categories include Irish Spring body wash for men, Softsoap brand Nutra-Oil moisturizing body wash and Mennen Speed Stick 24/7 Gametime deodorant. Fabuloso liquid cleaner, Suavitel fabric conditioner and Irish Spring bar soap each achieved record high market shares year to date.

New products planned for launch in the fourth quarter include Softsoap brand SPA Radiant body wash and liquid hand soap, Irish Spring Moisture Blast and Irish Spring Reviving Mint body washes, Softsoap brand Pink Grapefruit liquid hand soap and Mennen Speed Stick 24/7 Momentum deodorant.

Latin America (25% of Company Sales)

As reported, Latin American sales and unit volume grew 16.0% and 7.5%, respectively, in the third quarter. Excluding the divested bleach businesses, sales and unit volume grew 18.0% and 9.5%, respectively. All significant markets in the region contributed to the very strong volume gains, led by Mexico, Brazil, Venezuela, Central America, Argentina and Ecuador. Higher pricing added 3.0% and foreign exchange added 5.5%.

Latin American operating profit increased 13%, to an all-time record level even after a strong double-digit increase in advertising during the quarter.

Colgate continues to build its strong leadership in oral care throughout Latin America with its regional toothpaste market share at a record high year to date driven by market share gains in nearly every country. The multi-country rollout of Colgate Total Professional Clean toothpaste helped drive the regional market share for Colgate Total to an all-time high during the quarter. Colgate Max Fresh and Colgate Max White toothpastes also achieved share gains year to date. Colgate's leading share of the manual toothbrush market for the region is at a record high year to date, up 320 basis points versus year ago. Strong sales of Colgate 360° manual toothbrush throughout the region contributed to this success.

In other product categories, Plax Alcohol Free and Plax Ice mouthwashes, Palmolive Naturals Mint & Eucalyptus, Palmolive Nutri-Milk, Protex Deo 12 and Protex Propolis bar soaps, Lady Speed Stick Double Defense deodorant, Palmolive Caprice shampoo and Palmolive Nutri-Milk shower gel contributed to market share gains in the region.

Europe/South Pacific (25% of Company Sales)

Europe/South Pacific sales increased 12.0% to a record level, and unit volume grew 4.5%. Pricing was negative 2.0% and foreign exchange added 9.5%. Strong volume gains in the Gaba business, the United Kingdom, Denmark and Romania more than offset a volume decline in Germany due to challenging market conditions. Operating profit for the region grew 11% to an all-time record level, even after a significant increase in advertising during the quarter.

Colgate increased its oral care leadership in Europe/South Pacific led by toothpaste market share gains in France, Germany, United Kingdom, Italy, Spain, Greece, Austria, Norway, Romania, Denmark, Belgium, Poland and Australia. Successful premium products driving these share gains include Colgate Total, Colgate Total Professional Weekly Clean and Colgate Max Fresh toothpastes. Gaba's toothpaste market share also grew in many markets across the region, in both the food and pharmacy channels. In the

manual toothbrush category, strong sales of Colgate 360°, Colgate 360° Sensitive and Colgate Max Fresh toothbrushes strengthened Colgate's market leadership in this category for the region.

Recent premium innovations contributing to gains in other product categories include Palmolive Pure Cashmere shower gel, Colgate Plax Gentle Care mouth rinse, Soupline Aromatherapy fabric conditioner, and Ajax Professional bucket dilutable and Ajax Professional glass cleaners.

Greater Asia/Africa (17% of Company Sales)

Greater Asia/Africa sales and unit volume increased 18.5% and 9.5%, respectively. The strong volume gains were led by India, Russia, Turkey, Ukraine, South Africa, the Gulf States and the Greater China region, where volume increased 17% during the quarter. For the division as a whole, pricing increased 1.0% and foreign exchange added 8.0%. Operating profit for the region increased 38% to an all-time record level, even after a sizable increase in advertising spending during the quarter.

Colgate strengthened its oral care leadership in the Greater Asia region with 11 out of 14 countries reporting toothpaste market share gains versus year ago led by India, China, Philippines, Thailand, Ukraine, Russia and the rest of the CIS countries. Colgate's share of the manual toothbrush market also strengthened throughout the region with many countries achieving record high shares in the category. Successful new products driving the oral care growth include Colgate Total Professional Clean, Colgate Herbal Seabuckthorn, Darlie Double Action and Colgate Max White toothpastes, and Colgate 360°, Colgate 360° Sensitive and Colgate Twister Fresh manual toothbrushes.

New products contributing to growth in other categories in the region include Palmolive Thermal Spa Seabuckthorn shower gel, bar soap and liquid hand soap, Palmolive Pure Cashmere shower cream and bar soap, and Palmolive Floral and Odor Neutralizing liquid hand soap.

Hill's (13% of Company Sales)

Innovative new products and veterinary recommendations continue to drive growth at Hill's, a world leader in specialty pet food. Hill's sales and unit volume grew 12.0% and 5.0%, respectively, during the quarter. Pricing increased 4.0% and foreign exchange added 3.0%. Operating profit increased 10% even after significantly higher agricultural commodity costs during the quarter.

Consumption growth and market share gains in the U.S. specialty pet channel during the quarter were driven by strong sales of Science Diet Canine Large Breed and Science Diet Canine Lamb & Rice Small Bites. The relaunch of Science Diet Canine Nature's Best with upgraded all natural ingredients during the quarter is also off to a strong start. Science Diet Indoor Cat and Science Diet Light contributed to growth in feline. Prescription Diet c/d Multicare Feline, a therapeutic food for the nutritional management of cats with feline lower urinary tract disease, Prescription Diet d/d Canine and Prescription Diet j/d Canine drove growth in the U.S. veterinary channel.

Internationally, growth was strong led by Russia, South Africa, the United Kingdom, Italy, Spain, Germany, Australia and France. New pet food products contributing to the international growth include Prescription Diet j/d Canine and Feline, Science Plan Feline Chunks in Gravy pouches and Science Plan Neutered Cat, a veterinary exclusive product.

About Colgate-Palmolive: Colgate-Palmolive is a leading global consumer products company, tightly focused on Oral Care, Personal Care, Home Care and Pet Nutrition. Colgate sells its products in over 200 countries and territories around the world under such internationally recognized brand names as Colgate, Palmolive, Mennen, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, Elmex, Tom's of Maine, Ajax, Axion, Soupline, and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet. For more information about Colgate's global business, visit the Company's web site at http://www.colgate.com.

Unless otherwise indicated, all market share data included in this press release is as measured by ACNielsen.

This press release and the related webcast (other than historical information) may contain forward-looking statements. Such statements may relate, for example, to sales or volume growth, profit growth, earnings growth, financial goals, cost-reduction plans, estimated charges and savings associated with the 2004 Restructuring Program and new product introductions. These statements are made on the basis of our views and assumptions as of this time and we undertake no obligation to update these statements. We caution investors that any such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. Investors should consult the Company's filings with the Securities and Exchange Commission (including the information set forth under the captions "Risk Factors" and "Cautionary Statement on Forward-Looking Statements" in the Company's Form 10-K for the year ended December 31, 2006) for information about certain factors that could cause such differences. Copies of these filings may be obtained upon request from the Company's Investor Relations Department or the Company's web site at http://www.colgate.com.

Non-GAAP Financial Measures

The following provides information regarding the non-GAAP measures used in this earnings release:

To supplement Colgate's condensed consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America (GAAP), the Company has disclosed non-GAAP measures of operating results that exclude certain items. Net sales, cost of sales, gross profit margin, selling, general and administrative expenses, operating profit, operating profit margin, other (income) expense, the provision for income taxes and effective tax rate, net income, and earnings per share are discussed in this release both as reported (on a GAAP basis) and excluding the impact of certain items reported in the corporate segment, as explained below:

- The restructuring charges relate to the restructuring program that began in the fourth quarter of 2004 and is expected to be substantially completed by 2008 (the "2004 Restructuring Program"). These restructuring charges include separation-related costs, incremental depreciation and asset write-downs, and other costs related to the implementation of the 2004 Restructuring Program. In light of their nature and magnitude, the Company believes these items should be presented separately to enhance an investor's overall understanding of its ongoing operations.
- The four Other Items, which pertained to the nine months ended September 30, 2007, are comprised of the gain on sale of the Company's household bleach business in Latin America, a charge related to the limited voluntary product recall of certain Hill's feline products, tax adjustments which consist of the reduction of a tax loss carryforward valuation allowance in Brazil, partially offset by tax provisions for the recapitalization of certain overseas subsidiaries, all of which occurred in the first quarter of 2007, and a third quarter 2007 charge associated with certain pension obligations in accordance with Statement of Financial Accounting Standards (SFAS) No. 88, "Employers' Accounting for Settlement and Curtailments of Defined Benefit Pension Plans and for Termination Benefits" ("SFAS 88 charge"). The amount of each such excluded item for the three and nine months ended September 30, 2007 is set forth in the table entitled "Supplemental Consolidated Income Statement Information Other Items" included with this release. In light of their nature and magnitude, the Company believes that these four Other Items should be presented separately to enhance an investor's overall understanding of its ongoing operations.

Management believes these non-GAAP financial measures provide useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and are useful for period over period comparisons of such operations. The Company uses these financial measures internally in its budgeting process and as factors in determining compensation. While the Company believes that these financial measures are useful in evaluating the Company's business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a

substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similar measures presented by other companies. See "Consolidated Income Statement and Supplemental Information—Reconciliation Excluding the 2004 Restructuring Program and Other Items" for the three and nine months ended September 30, 2007 and 2006 included with this release for a reconciliation of these financial measures to the related GAAP measures.

Sales and unit volume growth, both worldwide and in relevant geographic divisions, and operating profit in certain geographic divisions are discussed in this release both as reported and excluding divestments. Management believes this provides useful information to investors as it allows comparisons of sales growth and volume growth and operating profit from ongoing operations. See "Geographic Sales Analysis, Percentage Changes—Third Quarter 2007 vs. 2006" for a comparison of sales excluding divestments to sales as reported in accordance with GAAP.

The Company defines free cash flow before dividends as net cash provided by operations less capital expenditures. As management uses this measure to evaluate the Company's ability to satisfy current and future obligations, repurchase stock, pay dividends and fund future business opportunities, the Company believes that it provides useful information to investors. Free cash flow before dividends is not a measure of cash available for discretionary expenditures since the Company has certain non-discretionary obligations such as debt service that are not deducted from the measure. Free cash flow before dividends is not a GAAP measurement and may not be comparable to similarly titled measures reported by other companies.

(See attached tables for third quarter results.)

Consolidated Income Statement and Supplemental Information

Reconciliation Excluding the 2004 Restructuring Program and Other Items

For the Three Months Ended September 30, 2007 and 2006

(in Millions Except Per Share Amounts) (Unaudited)

			2006									
			 Other Items (a) Excluding Restructuring & Other Items		structuring Other Items				ructuring	Excluding Restructuring		
Net sales	\$ 3,528.2	\$		\$ 	\$	3,528.2		3,143.7	\$		\$	3,143.7
Cost of sales	1,544.6		37.4			1,507.2		1,415.3		47.0		1,368.3
Gross profit	1,983.6		(37.4)	_		2,021.0		1,728.4		(47.0)		1,775.4
Gross profit margin	56.2%)				57.3%		55.0%				56.5%
Selling, general and administrative												
expenses	1,277.7		11.8			1,265.9		1,140.3		11.5		1,128.8
Other (income) expense, net	37.1		1.9	15.4		19.8		38.7		25.5		13.2
Operating profit	668.8		(51.1)	(15.4)		735.3		549.4		(84.0)		633.4
Operating profit margin	19.0%)				20.8%		17.5%				20.1%
Interest expense, net	38.5		_	_		38.5		41.2		_		41.2
Income before income taxes	630.3		(51.1)	(15.4)		696.8		508.2		(84.0)		592.2
Provision for income taxes	210.2		(14.8)	(5.4)		230.4		164.1		(25.5)		189.6
Effective tax rate	33.3%)				33.1%		32.3%				32.0%
Net income	420.1		(36.3)	(10.0)		466.4		344.1		(58.5)		402.6
Earnings per common share												
Basic	\$ 0.81	\$	(0.07)	\$ (0.02)	\$	0.90	\$	0.65	\$	(0.12)	\$	0.77
Diluted	\$ 0.77	\$	(0.07)	\$ (0.02)	\$	0.86	\$	0.63	\$	(0.10)	\$	0.73
Average common shares outstanding												
Basic	509.9		509.9	509.9		509.9		515.3		515.3		515.3
Diluted	542.4		542.4	542.4		542.4		550.4		550.4		550.4

(a) See Table 3 "Supplemental Consolidated Income Statement Information - Other Items" for details.

Note: Basic and diluted earnings per share for the "As Reported" and "Excluding Restructuring & Other Items" are computed independently for each quarter and the nine months presented. As a result of changes in shares outstanding during the year and rounding, the sum of the three quarters' earnings per share may not necessarily equal the earnings per share for the nine months. In addition, the impact of "Restructuring" and "Other Items" in 2007 on the basic and diluted earnings per share may not necessarily equal the earnings per share if calculated independently as a result of rounding.

Consolidated Income Statement and Supplemental Information

Reconciliation Excluding the 2004 Restructuring Program and Other Items

For the Nine Months Ended September 30, 2007 and 2006

(in Millions Except Per Share Amounts) (Unaudited)

		2007								2006						
		<u>Reported</u>	Res	tructuring	Othe	r Items (a)	Re	Excluding structuring <u>Other Items</u>	As	Reported	Rest	tructuring		xcluding tructuring		
Net sales	\$1	0,147.5	\$	—	\$	(2.1)	\$	10,149.6	\$	9,028.6	\$		\$	9,028.6		
Cost of sales		4,443.3		103.8		(1.1)		4,340.6		4,103.6		156.8		3,946.8		
Gross profit		5,704.2		(103.8)		(1.0)		5,809.0		4,925.0		(156.8)		5,081.8		
Gross profit margin		56.2%						57.2%		54.5%				56.3%		
Selling, general and administrative																
expenses		3,671.6		32.9		_		3,638.7		3,210.2		30.6		3,179.6		
Other (income) expense, net		55.1		15.7		(20.6)		60.0		187.0		130.3		56.7		
Operating profit		1,977.5		(152.4)		19.6		2,110.3		1,527.8		(317.7)		1,845.5		
Operating profit margin		19.5%					20.8		16.9%				20.4%			
Interest expense, net		121.6		_		_		121.6		119.8				119.8		
Income before income taxes		1,855.9	(152.4)			19.6	19.6 1,988.7		1,408.0			(317.7)		1,725.7		
Provision for income taxes		533.4	(44.5)		(65.8)			643.7		455.8		(96.5)	552.3			
Effective tax rate		28.7%						32.4%	32.4%				32.0%			
Net income		1,322.5		(107.9)		85.4		1,345.0		952.2		(221.2)		1,173.4		
Earnings per common share																
Basic	\$	2.55	\$	(0.21)	\$	0.17	\$	2.59	\$	1.81	\$	(0.43)	\$	2.24		
Diluted	\$	2.43	\$	(0.20)	\$	0.16	\$	2.47	\$	1.73	\$	(0.40)	\$	2.13		
Average common shares outstanding																
Basic		511.2		511.2		511.2		511.2		515.4		515.4		515.4		
Diluted		544.4		544.4		544.4		544.4		550.7		550.7		550.7		

(a) See Table 3 "Supplemental Consolidated Income Statement Information-Other Items" for details.

Note: Basic and diluted earnings per share for the "As Reported" and "Excluding Restructuring & Other Items" are computed independently for each quarter and the nine months presented. As a result of changes in shares outstanding during the year and rounding, the sum of the three quarters' earnings per share may not necessarily equal the earnings per share for the nine months. In addition, the impact of "Restructuring" and "Other Items" in 2007 on the basic and diluted earnings per share may not necessarily equal the earnings per share if calculated independently as a result of rounding.

Supplemental Consolidated Income Statement Information

Other Items

For the Three and Nine Months Ended September 30, 2007

(in Millions Except Per Share Amounts) (Unaudited)

	Three Months Ended September 30, 2007									
		ain on Ich Sale	Volu	Product untary ecall		Tax stments*	SFAS 88 Pension Charges		al Other Items	
Net sales	\$		\$		\$	—	\$ —	\$	—	
Cost of sales							—		—	
Gross profit				—		—				
Selling, general and administrative expenses				_		_	—			
Other (income) expense, net				_		_	15.4		15.4	
Operating profit				—		—	(15.4)		(15.4)	
Interest expense, net				—		—				
Income before income taxes				—		—	(15.4)		(15.4)	
Provision for income taxes				—		—	(5.4)		(5.4)	
Net income				—		—	(10.0)		(10.0)	
Earnings per common share										
Basic	\$		\$	_	\$	_	\$ (0.02)	\$	(0.02)	
Diluted	\$		\$	—	\$	—	\$ (0.02)	\$	(0.02)	

	Nine Months Ended September 30, 2007									
	Gain on Bleach Sale		Vo	Hill's Product Voluntary Recall		Tax istments*	SFAS 88 Pension Charges		al Other Items	
Net sales	\$		\$	(2.1)	\$	—	\$ —	\$	(2.1)	
Cost of sales		_		(1.1)		—	—		(1.1)	
Gross profit		_		(1.0)		_			(1.0)	
Selling, general and administrative expenses		—		_		_	_		_	
Other (income) expense, net		(48.6)		12.6		_	15.4		(20.6)	
Operating profit		48.6		(13.6)		_	(15.4)		19.6	
Interest expense, net		_		_		_	_		_	
Income before income taxes		48.6		(13.6)		_	(15.4)		19.6	
Provision for income taxes		18.9		(5.4)		(73.9)	(5.4)		(65.8)	
Net income		29.7		(8.2)		73.9	(10.0)		85.4	
Earnings per common share										
Basic	\$	0.06	\$	(0.02)	\$	0.15	\$ (0.02)	\$	0.17	
Diluted	\$	0.05	\$	(0.01)	\$	0.14	\$ (0.02)	\$	0.16	

* Reduction of tax loss carryforward valuation allowances in Brazil of \$94.6, partially offset by tax provisions for the recapitalization of certain overseas subsidiaries.

Condensed Consolidated Balance Sheets

As of September 30, 2007, December 31, 2006 and September 30, 2006

(Dollars in Millions) (Unaudited)

	September 30, 2007	December 31, 2006	September 30, 2006
Cash and cash equivalents	\$ 628.4	\$ 489.5	\$ 502.9
Receivables, net	1,758.0	1,523.2	1,446.3
Inventories	1,167.0	1,008.4	1,001.6
Other current assets	382.4	279.9	304.5
Property, plant and equipment, net	2,831.7	2,696.1	2,526.4
Other assets, including goodwill and intangibles	3,316.2	3,140.9	3,386.8
Total assets	\$ 10,083.7	\$ 9,138.0	\$ 9,168.5
Total debt	3,608.2	3,671.2	3,577.9
Other current liabilities	2,927.0	2,518.3	2,409.2
Other non-current liabilities	1,526.4	1,537.6	1,546.8
Total liabilities	8,061.6	7,727.1	7,533.9
Total shareholders' equity	2,022.1	1,410.9	1,634.6
Total liabilities and shareholders' equity	\$ 10,083.7	\$ 9,138.0	\$ 9,168.5
Supplemental Balance Sheet Information			
Debt less cash and marketable securities*	\$ 2,927.0	\$ 3,170.2	\$ 3,044.9
Working capital % of sales	2.4%	2.3%	2.6%

* Marketable securities of \$52.8, \$11.5 and \$30.1 as of September 30, 2007, December 31, 2006 and September 30, 2006, respectively, are included in Other current assets.

Condensed Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2007 and 2006

(Dollars in Millions) (Unaudited)

Not income\$ 1.322.5\$ 952.2Adjustments to reconcile net income to net cash provided by operations:(3.6)187.6Depreciation and amortization246.4243.5Gain before tax on sale of non-core product lines(48.6)-Stock-based compensation expense93.191.7Deferred income taxes(60.2)(24.5)Cash effects of changes in:(167.0)(122.9)Inventories(118.4)(128.9)Accounts payable and other accruals364.8122.8Other non-current assets and liabilities9.748.4Capital expenditures(327.1)(251.8)Sale of property and non-core product lines(327.1)(251.8)Sale of property and non-core product lines(30.6)(470.3)Payment for acquisitions, net of cash acquired(26.5)(200.0)Other(56.0)(21.4)Principal payments on debt(1.635.9)(1.011.3)Proceeds from itsuatare of debh1.50.4(1.11.3)Proceeds from itsuatare of debh(1.635.9)(1.011.3)Proceeds from exercise of stock options and excess tax benefits313.7226.5Net cash used in financing activities12.6(26.5)Net cash equivalents to elegination of period499.5340.7Cash and cash equivalents138.9162.2Cash and cash equivalents138.9162.2Capital expenditures(26.5)340.7Cash and cash equivalents138.9162.2Principal pa	Operating Activities	2007	2006
Adjustments to reconcile net income to net cash provided by operations:(3.6)187.6Restructuring, net of cash(3.6)187.6Depreciation and amorization246.4243.5Gain before tax on sale of non-core product lines(48.6)Stock-based compensation expense93.191.7Deferred income taxes(60.2)(24.5)Cash effects of changes in:(167.0)(122.9)Inventories(118.4)(128.9)Accounts payable and other accruals364.8122.8Other non-current assets and liabilities9.748.4Net cash provided by operations1.638.71.369.9Investing Activities(327.1)(251.8)Sale of property and non-core product lines106.02.9Payment for acquisitions, net of cash acquired(26.5)(2000.0)Other(56.6)(21.4)(21.4)Net cash used in investing activities(303.6)(470.3)Financing ActivitiesPrincipal payments on debt(1.635.9)(1.01.3)Proceeds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities138.91162.2Cash and eash equivalents12.6(26.6)Deviceds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities138.9162.2Cash and eash equivalents138.9162.2Cash and eash equivalents138.9162.2Cash and ea		\$ 1 322 5	\$ 952.2
Restructuring, net of cash(3.6)187.6Depreciation and amorization246.4243.5Gain before tax on sale of non-core product lines(48.6)-Stock-based compensation expense93.191.7Deferred income taxes(60.2)(24.5)Cash effects of changes in:(167.0)(122.9)Inventories(118.4)(128.9)Accounts payable and other accruals364.8122.8Other non-current assets and liabilities9.748.4Net cash provided by operations1,638.71,369.9Investing Activities(327.1)(251.8)Sale of property and non-core product lines(327.1)(251.8)Sale of property and non-core product lines(33.6)(470.3)Payment for acquisitions, net of cash acquired(26.5)(200.0)Other(55.0)(21.4)(21.4)Principal payments on debt(1,635.9)(1,011.3)Proceeds from issuance of debt1,530.41,116.7Dividends paid(550.4)(497.4)Proceeds form issuance of debt1,530.4(1,116.7)Dividends paid(550.4)(473.4)Proceeds from issuance of debt1,38.912.6Quictases of treasury shares(866.6)(601.3)Proceeds from issuance of debt138.912.6Quictases of textures on cash and cash equivalents138.9162.2Cash and cash equivalents138.9162.2Cash and cash equivalents138.9162.2Cash and		ψ 1,022.0	φ 552.2
Depreciation and amortization 246.4 243.5 Gain before tax on sale of non-core product lines (48.6) Stock-based compensation expense 93.1 91.7 Deferred income taxes (60.2) (24.5) Cash effects of changes in:($167.0)$ (122.9) Inventories (118.4) (128.9) Accounts payable and other acruals 364.8 122.8 Other non-current assets and liabilities 9.7 48.4 Net cash provided by operations $1,638.7$ $1,380.9$ Investing Activities (25.5) (200.0) Other non-current assets and liabilities 9.7 48.4 Net cash provided by operations 106.0 2.9 Payment for acquisitions, net of cash acquired (26.5) (200.0) Other (56.0) (21.4) Principal payments on debt $(1.635.9)$ $(1.011.3)$ Principal payments on debt (550.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from issuance of debt $1.33.9$ (25.6) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities 12.6 (22.6) Payment Cash equivalents 12.6 (22.6) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities 12.6 (22.6) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 <td></td> <td>(3.6)</td> <td>187.6</td>		(3.6)	187.6
Gain before tax on sale of non-core product lines (48.6) — Stock-based compensation expense 93.1 91.7 Deferred income taxes (60.2) (24.5) Cash effects of changes in: — — Receivables (167.0) (122.9) Inventories (118.4) (128.9) Accounts payable and other accruals 364.8 122.8 Other non-current assets and liabilities 9.7 48.4 Other non-current assets and liabilities 9.7 48.6 Capital expenditures (327.1) (251.8) Sale of property and non-core product lines (32.7) (26.5) (200.0) Other (56.0) (21.4) Payment for acquisitions, net of cash acquired (26.5) (200.0) Other (56.0) (21.4) Principal payments on debt (1,635.9) (1,011.3) Proceeds from insuance of debt 1,530.4 (1,11.3) Proceeds from issuance of debt 1,530.4 (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from issuance of debt 138.9 162.2			
Stock-based compensation expense 93.1 91.7 Deferred income taxes (60.2) (24.5) Cash effects of changes in: (60.2) (24.5) Receivables (167.0) (122.9) Inventories (118.4) (128.9) Accounts payable and other accruals 364.8 122.8 Other non-current assets and liabilities 9.7 48.4 Net cash provided by operations 1,638.7 1,369.9 Investing Activities (327.1) (251.8) Sale of property and non-core product lines (327.1) (251.8) Sale of property and non-core product lines (327.1) (251.8) Sale of property and non-core product lines (30.6) (470.3) Payment for acquisitions, net of cash acquired (26.5) (2000.0) Other (550.9) (1.11.6) (303.6) (470.3) Principal payments on debt (1,635.9) (1,011.3) Proceeds from issuance of debt 1,530.4 (1,116.7) Dividends paid (550.4) (497.4) Purchases of treasury shares (866.6) <t< td=""><td></td><td></td><td></td></t<>			
Deferred income taxes (60.2) (24.5) Cash effects of changes in: (167.0) (122.9) Inventories (118.4) (128.9) Accounts payable and other accuals 364.8 122.8 Other non-current assets and liabilities 9.7 448.4 Net cash provided by operations 1,638.7 1,369.9 Investing Activities (327.1) (251.8) Sale of property and non-core product lines (327.1) (251.8) Sale of property and non-core product lines (327.1) (26.5) (2000) Other (30.6) (21.4) (26.5) (2000) Other (30.6) (470.3) (470.3) Financing Activities (33.6) (470.3) Principal payments on debt (1,635.9) (1,011.3) Proceeds from issuance of debt 1,530.4 1,116.7 Dividends paid (55.0.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from issuance of debt 1,530.4 1,116.7 Dividends paid <td< td=""><td></td><td></td><td>91.7</td></td<>			91.7
Cash effects of changes in: Receivables(167.0)(122.9)Inventories(118.4)(128.9)Accounts payable and other accruals364.8122.8Other non-current assets and liabilities9.748.4Net cash provided by operations1,638.71,369.9Investing ActivitiesCapital expenditures(327.1)(251.8)Sale of property and non-core product lines106.02.9Payment for acquisitions, net of cash acquired(26.5)(200.0)Other(56.0)(21.4)Net cash used in investing activities(303.6)(470.3)Financing ActivitiesPrincipal payments on debt(1,635.9)(1,011.3)Proceeds from issuance of debt1,530.41,116.7Dividends paid(550.4)(497.4)Purchases of treasury shares(866.6)(601.3)Proceeds from excuss of and excess tax benefits313.7228.5Net cash used in financing activities(1,208.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents138.9162.2Cash and cash equivalents138.9162.2Cash and cash equivalents at end of period $\frac{489.5}{502.9}$ 340.7Supplemental Cash How Information1502.9Supplemental Cash provided by operations less capital expenditures) $\frac{32.71}{502.9}$ 502.9Supplemental Cash provided by operations\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)		(60.2)	(24.5)
Receivables (167.0) (122.9) Inventories (118.4) (128.9) Accounts payable and other acruals 364.8 122.8 Other non-current assets and liabilities 9.7 48.4 Net cash provided by operations 1,638.7 1,369.9 Investing Activities 7 48.4 Capital expenditures (327.1) (251.8) Sale of property and non-core product lines 106.0 2.9 Payment for acquisitions, net of cash acquired (26.5) (200.0) Other (56.0) (21.4) Net cash used in investing activities (303.6) (477.4) Principal payments on debt (1,635.9) (1,011.3) Proceeds from issuance of debt 1,530.4 1,116.7 Dividends paid (550.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities (1,208.8) (734.8) Effect of exchange rate changes on Cash and cash equivalents <	Cash effects of changes in:		. ,
Accounts payable and other accruals 364.8 122.8 Other non-current assets and liabilities 9.7 48.4 Net cash provided by operations $1,638.7$ $1,369.9$ Investing Activities 1 $1,638.7$ $1,369.9$ Capital expenditures (327.1) (251.8) Sale of property and non-core product lines 106.0 2.9 Payment for acquisitions, net of cash acquired (26.5) (200.0) Other (56.0) (21.4) Net cash used in investing activities (303.6) (470.3) Financing Activities (303.6) (470.3) Principal payments on debt $(1,635.9)$ $(1,011.3)$ Proceeds from issuance of debt $1,530.4$ $1,116.7$ Dividends paid (550.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities $(1,208.8)$ (734.8) Effect of exchange rate changes on Cash and cash equivalents 122.6 (2.6) Net increase in Cash and cash equivalents 122.6 (2.6) Supplemental Cash equivalents at end of period $\frac{5}{628.4}$ $\frac{5}{502.9}$ Supplemental Cash Flow Information 1 $1.530.7$ $$1.369.9$ Net cash provided by operations less capital expenditures) 5 $1.638.7$ $$1.369.9$ Less: Capital expenditures (327.1) (251.8) Free cash flow before dividends $$1.638.7$ $$$		(167.0)	(122.9)
Other non-current assets and liabilities 9.7 48.4 1,369.9Investing Activities1,638.71,369.9Investing Activities(327.1)(251.8)Sale of property and non-core product lines106.02.9Payment for acquisitions, net of cash acquired(26.5)(200.0)Other(56.0)(21.4)Net cash used in investing activities(303.6)(470.3)Financing Activities(303.6)(470.3)Principal payments on debt(1,635.9)(1,011.3)Proceeds from issuance of debt1,530.4(1,161.7)Dividends paid(550.4)(497.4)Purchases of treasury shares(866.6)(601.3)Proceeds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities(1,20.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents138.9162.2Cash and cash equivalents138.9162.2Cash and cash equivalents138.9162.2Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow Information\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)Free cash flow before dividends\$ 1,311.6\$ 1,118.1	Inventories	(118.4)	(128.9)
Net cash provided by operations $1,638.7$ $1,369.9$ Investing Activities(327.1)(251.8)Sale of property and non-core product lines 106.0 2.9 Payment for acquisitions, net of cash acquired (26.5) (200.0) Other (56.0) (21.4) Net cash used in investing activities (303.6) (470.3) Financing Activities (303.6) (470.3) Principal payments on debt $(1,635.9)$ $(1,011.3)$ Proceeds from issuance of debt $1,530.4$ $1,116.7$ Dividends paid (550.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities $(1,208.8)$ (734.8) Effect of exchange rate changes on Cash and cash equivalents 138.9 162.2 Cash and cash equivalents 138.9 162.2 Cash and cash equivalents 340.7 340.7 Cash and cash equivalents $5 628.4$ $$502.9$ Supplemental Cash Flow Information $$$1.638.7$ $$1.369.9$ Less: Capital expenditures (327.1) (251.8) Free cash flow before dividends (Net cash provided by operations less capital expenditures) $$$1.638.7$ $$1.369.9$ Less: Capital expenditures (327.1) (251.8) Free cash flow before dividends $$$1.118.1$ $$$1.118.1$	Accounts payable and other accruals	364.8	122.8
Investing Activities(327.1)(251.8)Sale of property and non-core product lines106.02.9Payment for acquisitions, net of cash acquired(26.5)(200.0)Other(26.5)(200.0)Other(303.6)(470.3)Financing ActivitiesPrincipal payments on debt(1,635.9)(1,011.3)Proceeds from issuance of debt1,530.41,116.7Dividends paid(550.4)(497.4)Purchases of treasury shares(866.6)(601.3)Proceeds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities(1,208.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents138.9162.2Cash and cash equivalents138.9162.2Cash and cash equivalents\$ 628.4\$ 502.9Supplemental Cash Flow Information\$ 1,638.7\$ 1,638.7Free cash flow before dividends (Net cash provided by operations less capital expenditures)\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)Free cash flow before dividends\$ 1,311.6\$ 1,118.1	Other non-current assets and liabilities	9.7	48.4
Capital expenditures (327.1) (251.8) Sale of property and non-core product lines106.02.9Payment for acquisitions, net of cash acquired (26.5) (200.0) Other (56.0) (21.4) Net cash used in investing activities (303.6) (470.3) Financing ActivitiesPrincipal payments on debt $(1,635.9)$ $(1,011.3)$ Proceeds from issuance of debt $1,530.4$ $1,116.7$ Dividends paid (550.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities $(1,208.8)$ (734.8) Effect of exchange rate changes on Cash and cash equivalents 138.9 162.2 Cash and cash equivalents 138.9 162.2 Cash and cash equivalents at beginning of period 489.5 340.7 Cash and cash equivalents at end of period $$ 628.4$ $$ 502.9$ Supplemental Cash Flow Information $$ 1,538.7$ $$ 1,369.9$ Less: Capital expenditures (327.1) (251.8) Free cash flow before dividends (Net cash provided by operations less capital expenditures) $$ 1,311.6$ $$ 1,118.1$ Free cash flow before dividends $$ 1,311.6$ $$ 1,118.1$	Net cash provided by operations	1,638.7	1,369.9
Capital expenditures (327.1) (251.8) Sale of property and non-core product lines106.02.9Payment for acquisitions, net of cash acquired (26.5) (200.0) Other (56.0) (21.4) Net cash used in investing activities (303.6) (470.3) Financing ActivitiesPrincipal payments on debt $(1,635.9)$ $(1,011.3)$ Proceeds from issuance of debt $1,530.4$ $1,116.7$ Dividends paid (550.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities $(1,208.8)$ (734.8) Effect of exchange rate changes on Cash and cash equivalents 138.9 162.2 Cash and cash equivalents 138.9 162.2 Cash and cash equivalents at beginning of period 489.5 340.7 Cash and cash equivalents at end of period $$ 628.4$ $$ 502.9$ Supplemental Cash Flow Information $$ 1,538.7$ $$ 1,369.9$ Less: Capital expenditures (327.1) (251.8) Free cash flow before dividends (Net cash provided by operations less capital expenditures) $$ 1,311.6$ $$ 1,118.1$ Free cash flow before dividends $$ 1,311.6$ $$ 1,118.1$	Investing Activities		
Payment for acquisitions, net of cash acquired (26.5) (200.0) Other (56.0) (21.4) Net cash used in investing activities (303.6) (470.3) Financing ActivitiesPrincipal payments on debt $(1,635.9)$ $(1,011.3)$ Proceeds from issuance of debt $1,530.4$ $1,116.7$ Dividends paid (550.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities $(1,208.8)$ (734.8) Effect of exchange rate changes on Cash and cash equivalents 138.9 162.2 Cash and cash equivalents 138.9 162.2 Cash and cash equivalents 340.7 Supplemental Cash Flow Information $$628.4$ $$502.9$ Net cash provided by operations less capital expenditures) $$1,638.7$ $$1,369.9$ Less: Capital expenditures (327.1) (251.8) Free cash flow before dividends $$1,118.1$	-	(327.1)	(251.8)
Payment for acquisitions, net of cash acquired (26.5) (200.0) Other (56.0) (21.4) Net cash used in investing activities (303.6) (470.3) Financing ActivitiesPrincipal payments on debt $(1,635.9)$ $(1,011.3)$ Proceeds from issuance of debt $1,530.4$ $1,116.7$ Dividends paid (550.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities $(1,208.8)$ (734.8) Effect of exchange rate changes on Cash and cash equivalents 138.9 162.2 Cash and cash equivalents 138.9 162.2 Cash and cash equivalents 340.7 Supplemental Cash Flow Information $$628.4$ $$502.9$ Net cash provided by operations less capital expenditures) $$1,638.7$ $$1,369.9$ Less: Capital expenditures (327.1) (251.8) Free cash flow before dividends $$1,118.1$	Sale of property and non-core product lines	106.0	2.9
Net cash used in investing activities(303.6)(470.3)Financing Activities1(1,635.9)(1,011.3)Principal payments on debt1,530.41,116.7Dividends paid(550.4)(497.4)Purchases of treasury shares(866.6)(601.3)Proceeds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities(1,208.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents12.6(2.6)Net increase in Cash and cash equivalents138.9162.2Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at ned of period\$ 628.4\$ 502.9Supplemental Cash Flow InformationTTFree cash flow before dividends (Net cash provided by operations less capital expenditures)\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)Free cash flow before dividends\$ 1,118.1		(26.5)	(200.0)
Financing ActivitiesPrincipal payments on debt(1,635.9)(1,011.3)Proceeds from issuance of debt1,530.41,116.7Dividends paid(550.4)(497.4)Purchases of treasury shares(866.6)(601.3)Proceeds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities(1,208.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents12.6(2.6)Net increase in Cash and cash equivalents138.9162.2Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow InformationFree cash flow before dividends (Net cash provided by operations less capital expenditures)\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)\$ 1,118.1Free cash flow before dividends\$ 1,118.1\$ 1,118.1	Other	(56.0)	(21.4)
Principal payments on debt(1,635.9)(1,011.3)Proceeds from issuance of debt1,530.41,116.7Dividends paid(550.4)(497.4)Purchases of treasury shares(866.6)(601.3)Proceeds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities(1,208.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents12.6(2.6)Net increase in Cash and cash equivalents138.9162.2Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow Information\$ 1,638.7\$ 1,369.9Free cash flow before dividends (Net cash provided by operations less capital expenditures)\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)Free cash flow before dividends\$ 1,118.1	Net cash used in investing activities	(303.6)	(470.3)
Proceeds from issuance of debt1,530.41,116.7Dividends paid(550.4)(497.4)Purchases of treasury shares(866.6)(601.3)Proceeds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities(1,208.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents12.6(2.6)Net increase in Cash and cash equivalents138.9162.2Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow Information\$ 1,638.7\$ 1,369.9Free cash flow before dividends (Net cash provided by operations less capital expenditures)\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)Free cash flow before dividends\$ 1,311.6\$ 1,118.1	Financing Activities		
Dividends paid (550.4) (497.4) Purchases of treasury shares (866.6) (601.3) Proceeds from exercise of stock options and excess tax benefits 313.7 258.5 Net cash used in financing activities (1,208.8) (734.8) Effect of exchange rate changes on Cash and cash equivalents 12.6 (2.6) Net increase in Cash and cash equivalents 138.9 162.2 Cash and cash equivalents at beginning of period 489.5 340.7 Cash and cash equivalents at end of period \$ 628.4 \$ 502.9 Supplemental Cash Flow Information \$ 1,638.7 \$ 1,369.9 Free cash flow before dividends (Net cash provided by operations less capital expenditures) \$ (327.1) (251.8) Free cash flow before dividends \$ 1,311.6 \$ 1,118.1	Principal payments on debt	(1,635.9)	(1,011.3)
Purchases of treasury shares(866.6)(601.3)Proceeds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities(1,208.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents12.6(2.6)Net increase in Cash and cash equivalents138.9162.2Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow InformationFree cash flow before dividends (Net cash provided by operations less capital expenditures)\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)(251.8)Free cash flow before dividends\$ 1,118.1\$ 1,118.1	Proceeds from issuance of debt	1,530.4	1,116.7
Proceeds from exercise of stock options and excess tax benefits313.7258.5Net cash used in financing activities(1,208.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents12.6(2.6)Net increase in Cash and cash equivalents138.9162.2Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow InformationFree cash flow before dividends (Net cash provided by operations less capital expenditures) Net cash provided by operations\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)(251.8)Free cash flow before dividends\$ 1,311.6\$ 1,118.1	Dividends paid	(550.4)	(497.4)
Net cash used in financing activities(1,208.8)(734.8)Effect of exchange rate changes on Cash and cash equivalents12.6(2.6)Net increase in Cash and cash equivalents138.9162.2Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow InformationFree cash flow before dividends (Net cash provided by operations less capital expenditures)\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)Free cash flow before dividends\$ 1,311.6\$ 1,118.1	Purchases of treasury shares	(866.6)	(601.3)
Effect of exchange rate changes on Cash and cash equivalents12.6(2.6)Net increase in Cash and cash equivalents138.9162.2Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow Information\$ 1,638.7\$ 1,369.9Free cash flow before dividends (Net cash provided by operations less capital expenditures)\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)Free cash flow before dividends\$ 1,118.1	Proceeds from exercise of stock options and excess tax benefits	313.7	258.5
Net increase in Cash and cash equivalents138.9162.2Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow InformationFree cash flow before dividends (Net cash provided by operations less capital expenditures) Net cash provided by operations\$ 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)Free cash flow before dividends\$ 1,311.6\$ 1,118.1	Net cash used in financing activities	(1,208.8)	(734.8)
Cash and cash equivalents at beginning of period489.5340.7Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow Information**Free cash flow before dividends (Net cash provided by operations less capital expenditures) Net cash provided by operations* 1,638.7\$ 1,369.9Less: Capital expenditures(327.1)(251.8)Free cash flow before dividends\$ 1,311.6\$ 1,118.1	Effect of exchange rate changes on Cash and cash equivalents	12.6	(2.6)
Cash and cash equivalents at end of period\$ 628.4\$ 502.9Supplemental Cash Flow Information*Free cash flow before dividends (Net cash provided by operations less capital expenditures) Net cash provided by operations Less: Capital expenditures\$ 1,638.7\$ 1,369.9Cash flow before dividends(327.1)(251.8)Free cash flow before dividends\$ 1,311.6\$ 1,118.1	Net increase in Cash and cash equivalents	138.9	162.2
Supplemental Cash Flow InformationFree cash flow before dividends (Net cash provided by operations less capital expenditures)Net cash provided by operationsLess: Capital expenditures(327.1)Free cash flow before dividendsFree cash flow before dividends\$ 1,311.6	Cash and cash equivalents at beginning of period	489.5	340.7
Free cash flow before dividends (Net cash provided by operations less capital expenditures)\$ 1,638.7\$ 1,369.9Net cash provided by operations(327.1)(251.8)Less: Capital expenditures\$ 1,311.6\$ 1,118.1	Cash and cash equivalents at end of period	\$ 628.4	\$ 502.9
Net cash provided by operations \$ 1,638.7 \$ 1,369.9 Less: Capital expenditures (327.1) (251.8) Free cash flow before dividends \$ 1,311.6 \$ 1,118.1	Supplemental Cash Flow Information		
Less: Capital expenditures (327.1) (251.8) Free cash flow before dividends \$ 1,311.6 \$ 1,118.1	Free cash flow before dividends (Net cash provided by operations less capital expenditures)		
Free cash flow before dividends\$ 1,311.6\$ 1,118.1	Net cash provided by operations	\$ 1,638.7	\$ 1,369.9
	Less: Capital expenditures	(327.1)	(251.8)
Income taxes paid \$ 469.3 \$ 497.9	Free cash flow before dividends	\$ 1,311.6	\$ 1,118.1
	Income taxes paid	\$ 469.3	\$ 497.9

Segment Information

For the Three and Nine Months Ended September 30, 2007 and 2006

(Dollars in Millions) (Unaudited)

		nths Ended 1ber 30,	Nine Months Ended September 30,		
	2007	2006	2007	2006	
Net sales					
Oral, Personal and Home Care					
North America	\$ 687.7	\$ 668.1	\$ 2,021.6	\$1,933.1	
Latin America	893.7	769.3	2,544.9	2,203.1	
Europe/South Pacific	875.3	779.8	2,501.8	2,192.7	
Greater Asia/Africa	607.2	512.5	1,726.0	1,489.6	
Total Oral, Personal and Home Care	\$3,063.9	\$2,729.7	\$ 8,794.3	\$7,818.5	
Pet Nutrition	464.3	414.0	1,353.2	1,210.1	
Total Net sales	\$3,528.2	\$3,143.7	\$10,147.5	\$9,028.6	
		nths Ended 1ber 30, 2006	Nine Mont Septeml 2007		
Operating profit					
Oral, Personal and Home Care					
North America	\$ 171.0	\$ 143.5	\$ 484.8	\$ 418.7	
Latin America	250.2	220.8	742.4	651.9	
Europe/South Pacific	199.9	179.5	565.7	495.1	
Greater Asia/Africa	90.8	65.9	259.2	199.3	
Total Oral, Personal and Home Care	\$ 711.9	\$ 609.7	\$ 2,052.1	\$1,765.0	
Pet Nutrition	116.9	106.7	354.5	318.4	
Corporate	(160.0)	(167.0)	(429.1)	(555.6)	
Total Operating profit	\$ 668.8	\$ 549.4	\$ 1,977.5	\$1,527.8	

The Company evaluates segment performance based on several factors, including Operating profit. The Company uses Operating profit as a measure of operating segment performance because it excludes the impact of corporate-driven decisions related to interest expense and income taxes. Corporate operations include research and development costs, unallocated overhead costs, stock-based compensation related to stock options and restricted stock awards, restructuring and related implementation costs, SFAS 88 pension charges and gains and losses on sales of non-core brands and assets.

For the three months ended September 30, 2007 and 2006, Corporate operating expenses include \$51.1 and \$84.0 of charges related to the Company's 2004 Restructuring Program, respectively. For the nine months ended September 30, 2007 and 2006, Corporate operating expenses include \$152.4 and \$317.7 of charges related to the Company's 2004 Restructuring Program, respectively. Additionally, Corporate operating expenses for the three and nine months ended September 30, 2007 were increased by SFAS 88 pension charges of \$15.4. For the nine months ended September 30, 2007, Corporate operating expenses were reduced by a \$48.6 gain related to the sale of the Company's household bleach business in Latin America.

As a result of a limited voluntary recall of Hill's product in March 2007, Pet Nutrition Net sales for the nine months ended September 30, 2007 were reduced by \$2.1 and Corporate operating expenses increased by \$13.6.

Table 7

Colgate-Palmolive Company

Geographic Sales Analysis

Percentage Changes - Third Quarter 2007 vs 2006

September 30, 2007

(Unaudited)

				TS OF SALES C IRD QUARTER	HANGE				TS OF SALES C INE MONTHS	HANGE
Region	3rd Qtr Sales Change <u>As Reported</u>	3rd Qtr Sales Change <u>Ex-Divestment</u>	Ex-Divested Volume	Pricing Coupons Consumer & Trade Incentives	Exchange	9 Months Sales Change <u>As Reported</u>	9 Months Sales Change <u>Ex-Divestment</u>	Ex-Divested Volume	Pricing Coupons Consumer & Trade Incentives	Exchange
Total Company	12.0%	13.0%	6.5%	1.0%	5.5%	12.5%	13.0%	7.5%	1.0%	4.5%
Europe/South Pacific	12.0%	12.0%	4.5%	(2.0)%	9.5%	14.0%	14.0%	6.0%	(1.5)%	9.5%
Latin America	16.0%	18.0%	9.5%	3.0%	5.5%	15.5%	17.0%	12.0%	1.5%	3.5%
Greater Asia/Africa	18.5%	18.5%	9.5%	1.0%	8.0%	16.0%	16.0%	9.0%	1.5%	5.5%
Total International	15.5%	16.0%	7.5%	1.0%	7.5%	15.0%	15.5%	9.0%	0.5%	6.0%
North America	3.0%	4.5%	3.0%	0.5%	1.0%	4.5%	6.0%	5.5%	0.5%	0.0%
Total CP Products	12.0%	13.0%	6.5%	0.5%	6.0%	12.5%	13.0%	8.0%	0.5%	4.5%
Hill's	12.0%	12.0%	5.0%	4.0%	3.0%	12.0%	12.0%	5.0%	4.5%	2.5%